Go to article: Home | Genomic projects exploit scaleGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Owen Mumford Company InsightGo to article: Owen MumfordGo to article: CommentGo to article: Disappointing results signal setbacks for Alzheimer’s treatmentsGo to article: Heart failure: charting the clinical trial landscape in the past decadeGo to article: Russia’s focus on domestic pharma production could shield it from sanctionsGo to article: Delayed EMA approval: improved safety or lack of access to therapeutics?Go to article: CMOs and US Government invest in continuous manufacturingGo to article: BaxterGo to article: CSafe GlobalGo to article: NiproGo to article: In DepthGo to article: Genomic projects exploit scale as clinical applications play catch-upGo to article: Tracing the rise of orphan drug designations over almost 40 yearsGo to article: How much does it hurt—measuring pain in clinical trialsGo to article: Neglected tropical diseases: non-profits lead the way as private sectors lagsGo to article: CMO Moves: Regulatory catalysts for drug manufacturing-JulyGo to article: Pfeiffer VacuumGo to article: Biolife SolutionsGo to article: In DataGo to article: Supply chain & logistics innovation among pharma companiesGo to article: Hiring boom in pharmaceutical industry IoT rolesGo to article: Regenerative medicine deals decreased in the pharma industryGo to article: Digitalization jobs in the pharmaceutical industryGo to article: EventsGo to article: Next issue